SCHEMBL7574816

SCHEMBL7574816

CC(C)c1cccc(C(C)C)c1OS(=O)(=O)NC(=O)C1CC1c1ccccc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7566736 0.79 SOAT2 (0.60)
SCHEMBL14194817 0.78
SCHEMBL7570200 0.75 SOAT2 (0.50)
SCHEMBL7575399 0.74 SOAT2 (0.54)
SCHEMBL9708149 0.73
SCHEMBL7570240 0.73 HTR1E (0.49)
SCHEMBL7567363 0.73 HTR1E (0.49)
SCHEMBL7567472 0.73
SCHEMBL7568224 0.73 SOAT2 (0.56)
SCHEMBL7568088 0.73 SOAT2 (0.56)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020183384-A1 Methods of treating nuclear factor-kappa B mediated diseases and disorders CORNICELLI JOSEPH ANTHONY (US) 2002-12-05 US disclosed
CN-1370526-A Treating method of nuclear factor-KB mediated diseases and dysfuction WANER LONGBER CO (US) 2002-09-25 CN disclosed
EP-1236468-A1 Sulfonylaminocarbonyl derivatives for the treatment of nuclear factor-kappa B mediated diseases and disorders WARNER-LAMBERT COMPANY (US) 2002-09-04 EP disclosed